In vivo pharmacology of [βAla 8]neurokinin A-(4-10), a selective NK-2 tachykinin receptor agonist

We studied the effect of [βAla 8]neurokinin A-(4–10), a newly developed selective NK-2 tachykinin receptor agonist, on various parameters in anaesthetized rats (blood pressure, urinary bladder motility, plasma extravasation) and guinea-pigs (salivation, increase of pulmonary insufflation pressure) as compared to the response produced by tachykinins. [βAla 8]Neurokinin A-(4–10) was as active as, or more active than, neurokinin A (NKA) or NKA-(4–10) in producing rat bladder contraction or bronchospasm in guinea-pigs, two effects known to involve activation of NK-2 receptors. On the other hand, the synthetic peptide was weakly active, if active at all, in producing hypotension or plasma extravasation in the rat bladder as well as salivation in guinea-pigs, effects known to involve activation of NK-1 receptors. These findings provide evidence that [βAla 8]NKA-(4–10) acts as a selective NK-2 agonist in vivo and that it can be used to explore the distribution and function of NK-2 receptors.